Ramucirumab
As of the edition of 20 October 2026, Ramucirumab is an antibody: marketed, first approved in 2014 (US); acts on KDR; US protection ended in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Antibody
- Brand name
- Cyramza
- First approved
- 21 April 2014 (US)
- Approvals on record
- 10 in 4 regions
- Holder of the most recent approval
- Eli Lilly; 2 holders in all
- Registered trials
- 158, 17 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue
US protection
US protection ended in 2026.
The orphan exclusivity ended in 2026 (it covers one use only). The application that gives this date is held by Eli Lilly.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Ramucirumab.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 2 | 1 | 0 |
| Phase 1 | 34 | 22 | 7 | 3 |
| Phase 2 | 96 | 48 | 27 | 13 |
| Phase 3 | 22 | 14 | 6 | 1 |
| All trials | 158 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Applicant and Lead sponsor of trials | 2014 to now |